We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
6 May 2021
Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients has closed an oversubscribed USD 57m Series C financing round. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining several of the company’s existing investors.
The VISCHER-team advising Oculis is led by Matthias Staehelin (Partner) with Vincent Reardon (Managing Associate) (both Corporate).
Press release
Categories: China Desk, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...